Company profile for Harmony Biosciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Harmony Biosciences, LLC, is a private biopharmaceutical company headquartered in Plymouth Meeting, PA. The company was established in October 2017 with a vision to develop and commercialize novel treatment options for people living with rare diseases. With a focus on the central nervous system, including disorders of sleep and wakefulness, Harmony Biosciences is currently working to advance the understanding of narcolepsy and...
Harmony Biosciences, LLC, is a private biopharmaceutical company headquartered in Plymouth Meeting, PA. The company was established in October 2017 with a vision to develop and commercialize novel treatment options for people living with rare diseases. With a focus on the central nervous system, including disorders of sleep and wakefulness, Harmony Biosciences is currently working to advance the understanding of narcolepsy and provide information and resources to people who live with, and healthcare professionals who treat, this chronic, debilitating neurologic disorder.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
630 W. Germantown Pike, Suite 215 Plymouth Meeting, PA 19462
Telephone
Telephone
(484) 539-9800
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.biospace.com/drug-development/harmonys-dravet-drug-halves-monthly-seizures-in-late-stage-study

BIOSPACE
03 Dec 2025

https://www.businesswire.com/news/home/20251124261066/en/Harmony-Biosciences-Announces-Positive-Results-From-the-Pivotal-Bioequivalence-Study-for-Pitolisant-Gastro-Resistant-Formulation

BUSINESSWIRE
24 Nov 2025

https://www.businesswire.com/news/home/20251119313237/en/Harmony-Biosciences-Announces-Initiation-of-First-In-Human-Study-With-Potential-Best-In-Class-Orexin-2-Receptor-Agonist-BP1.15205-for-Central-Disorders-of-Hypersomnolence

BUSINESSWIRE
19 Nov 2025

https://www.businesswire.com/news/home/20251118552477/en/Harmony-Biosciences-to-Participate-in-Upcoming-Investor-Conferences

BUSINESSWIRE
18 Nov 2025

https://www.businesswire.com/news/home/20251104727906/en/Harmony-Biosciences-Reports-Strong-Q3-2025-Financial-Results-Recently-Raised-2025-Revenue-Guidance-to-%24845-%24865M

BUSINESSWIRE
04 Nov 2025

https://www.fiercebiotech.com/biotech/harmony-halts-genetic-disease-program-following-ph-3-fragile-x-failure

FIERCE BIOTECH
04 Nov 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty